# FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

> **NCT03422510** · PHASE2 · COMPLETED · sponsor: **Complexa, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Primary Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** CXA-10

## Key facts

- **NCT ID:** NCT03422510
- **Lead sponsor:** Complexa, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-15
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03422510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03422510, "FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03422510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*